SEARCH

SEARCH BY CITATION

References

  • 1
    Spencer K, Souter V, Tul N, Snijders R, Nicolaides KH. A screening program for trisomy 21 at 10–14 weeks using fetal nuchal translu-cency, maternal serum free β human chorionic gonadotropin and pregnancy-associated plasma protein-A. Ultrasound Obstet Gynecol 1999; 13: 231237.
  • 2
    Lieppman RE, Williams MA, Cheng EY et al. An association between elevated levels of human chorionic gonadotropin in the midtrimester and adverse pregnancy outcome. Am J Obstet Gynecol 1983; 168: 18521856.
  • 3
    Said ME, Campbell DM, Azzam ME, MacGillivray I. Beta-human chorionic gonadotrophin levels before and after the development of pre-eclampsia. Br J Obstet Gynaecol 1984; 91: 772775.
  • 4
    Sorensen TK, Williams MA, Zingheim RW, Clernent SJ, Hickok DE. Elevated second-trimester human chorionic gonadotropin and subsequent pregnancy-induced hypertension. Am J Obstet Gynecol 1993; 169: 834838.
  • 5
    Wenstrom KD, Owen J, Boots LR, Dubard MB. Elevated second trimester human chorionic gonadotropin levels in association with poor pregnancy outcome. Am J Obstet Gynecol 1994; 171:10381041.
  • 6
    Yaron Y, Cherry M, Kramer RL et al. Second-trimester maternal serum marker screening: Maternal serum α-fetoprotein, β-human chorionic gonadotropin, estriol, and their various combinations as predictors of pregnancy outcome. Am J Obstet Gynecol 1999; 181: 968974.
  • 7
    Spencer K. HCG and its subunits in first trimester Down Syndrome screening. In: GrudzinskasJG, WardRHT, editors. Screening for Down Syndrome in the First Trimester. London : RCOG Press, 1997:117131.
  • 8
    Berry E, Aitken DA, Crossley JA, Macri JN, Connor JM. Screening for Down's syndrome: changes in marker levels and detection rates between first and second trimesters. Br J Obstet Gynaecol 1997; 104:811817.
  • 9
    Stergaard JG, Sinosich MJ, Bugge M, Madsen LT, Teisner B, Grudzinskas JG. Pregnancy-associated plasma protein A in the prediction of early pregnancy failure. Am J Obstet Gynecol 1983; 145: 6769.
  • 10
    Westergaard JG, Teisner B, Sinosich MJ, Madsen LT, Grudzinskas JG. Does ultrasound examination render biochemical tests obsolete in the prediction of early pregnancy failure Br J Obstet Gynaecol 1985; 92: 7783.
  • 11
    Ruge S, Pedersen JF, Sorensen S, Lange AP. Can pregnancy-associated plasma protein A (PAPP-A) predict the outcome of pregnancy in women with threatened abortion and confirmed fetal viability Acta Obstet Gynecol Scand 1990; 69: 589559.
  • 12
    Cuckle HS, Sehmi IK, Jones RG, Mason G. Low maternal serum pregnancy associated plasma protein A and fetal viability. Prenat Diagn 1999; 19:787792.
  • 13
    Johnson MR, Riddle AF, Grudzinskas JG, Sharma V, Collins WP, Nicolaides KH. Reduced circulating placental protein concentrations during the first trimester are associated with preterm labour and low birth weight. Human Reprod 1993; 8: 19421947.
  • 14
    Pedersen JF, Sorensen S, Ruge S. Human placental lactogen and pregnancy-associated plasma protein A in the first trimester and subsequent fetal growth restriction. Acta Obstet Gynecol Scand 1995; 74:505508.
  • 15
    World Health Organization Expert Committee on Diabetes Mellitus (1980) Technical Report Series 646. Geneva : WHO, p. 8.
  • 16
    Davey DA, MacGillivray I. The classification and definition of the hypertensive disorders of pregnancy. Am J Obstet Gynecol 1988; 158: 892898.
  • 17
    Yudkin PL, Aboualfa M, Eyre JA, Redman CW, Wilkinson AR. New birthweight and head circumference centiles for gestational ages 24 to 42 weeks. Early Hum Dev 1987; 15:4552.
  • 18
    Wald NJ, Cuckle HS, Densem JW, Stone RB. Maternal serum unconjugated oestriol and human chorionic gonadotrophin levels in pregnancies with insulin-dependent diabetes: implications for screening for Down's syndrome. Br J Obstet Gynaecol 1992; 99: 5153.
  • 19
    Pedersen JF, Sorensen S, Molsted-Pedersen L. Serum levels of human placental lactogen, pregnancy-associated plasma protein A and endometrial secretory protein PP14 in first trimester of diabetic pregnancy. Acta Obstet Gynecol Scand 1998; 77: 155158.
  • 20
    Tul N, Spencer K, Noble P, Chan C, Nicolaides KH. Screening for tri-somy 18 by fetal nuchal translucency and maternal serum free beta hCG, pregnancy associated plasma protein A at 10–14 weeks of gestation. Prenat Diagn 1999; 19: 10351042.
  • 21
    Spencer K, Ong C, Skentou H, Liao AW, Nicolaides KH. Screening for trisomy 13 by fetal nuchal translucency and maternal serum free beta hCG, pregnancy associated plasma protein A at 10–14 weeks of gestation. Prenat Diagn 2000; 20: 411416.
  • 22
    Spencer K, Liao AW, Skentou H, Cicero S, Nicolaides KH. Screening for triploidy by fetal nuchal translucency and maternal serum free β human chorionic gonadotropin, pregnancy associated plasma protein A at 10–14 weeks of gestation. Prenat Diagn 2000; 20: 495499.
  • 23
    Ahong T, De Wolf F, Robertson WB, Brosens I. Inadequate maternal vascular response to placentation in pregnancies complicated by pre-eclampsia and by small-for-gestational age infants. Br J Obstet Gynaecol 1986; 93: 10491059.
  • 24
    Morssink LP, Kornman LH, Hallahan TW et al. Maternal serum levels of free β human chorionic gonadotropin, pregnancy associated plasma protein A in the first trimester of pregnancy are not associated with subsequent fetal growth retardation or preterm delivery. Prenat Diagn 1998; 18: 147152.